BR112023005708A2 - Compostos e seu uso no tratamento do câncer - Google Patents
Compostos e seu uso no tratamento do câncerInfo
- Publication number
- BR112023005708A2 BR112023005708A2 BR112023005708A BR112023005708A BR112023005708A2 BR 112023005708 A2 BR112023005708 A2 BR 112023005708A2 BR 112023005708 A BR112023005708 A BR 112023005708A BR 112023005708 A BR112023005708 A BR 112023005708A BR 112023005708 A2 BR112023005708 A2 BR 112023005708A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- cancer
- treatment
- relates
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063085384P | 2020-09-30 | 2020-09-30 | |
| PCT/EP2021/076752 WO2022069520A1 (en) | 2020-09-30 | 2021-09-29 | Compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023005708A2 true BR112023005708A2 (pt) | 2023-05-02 |
Family
ID=78085628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023005708A BR112023005708A2 (pt) | 2020-09-30 | 2021-09-29 | Compostos e seu uso no tratamento do câncer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230374007A1 (https=) |
| EP (1) | EP4221756A1 (https=) |
| JP (1) | JP2023543299A (https=) |
| KR (1) | KR20230079408A (https=) |
| CN (1) | CN116249554A (https=) |
| AU (2) | AU2021353968B2 (https=) |
| BR (1) | BR112023005708A2 (https=) |
| CA (1) | CA3195695A1 (https=) |
| CL (1) | CL2023000881A1 (https=) |
| CO (1) | CO2023005188A2 (https=) |
| CR (1) | CR20230185A (https=) |
| DO (1) | DOP2023000062A (https=) |
| EC (1) | ECSP23030959A (https=) |
| IL (1) | IL301626A (https=) |
| MX (1) | MX2023003564A (https=) |
| PE (1) | PE20230782A1 (https=) |
| WO (1) | WO2022069520A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115141179B (zh) * | 2021-03-31 | 2024-09-13 | 江苏恒瑞医药股份有限公司 | 一种新型苯并杂环基类衍生物、其制备方法及其在医药上的应用 |
| US20250205344A1 (en) | 2022-03-24 | 2025-06-26 | Glaxosmithkline Intellectual Property Development Limited | 2,4-dioxotetrahydropyrimidinyl deratives as degrons in protacs |
| USD1018747S1 (en) * | 2022-04-15 | 2024-03-19 | Puttshack LTD | Miniature golf hole |
| USD1020957S1 (en) * | 2022-04-15 | 2024-04-02 | Puttshack LTD | Miniature golf hole |
| USD1018746S1 (en) * | 2022-04-15 | 2024-03-19 | Puttshack LTD | Miniature golf hole |
| USD1018676S1 (en) * | 2022-04-15 | 2024-03-19 | Puttshack LTD | Miniature golf hole |
| US20260098043A1 (en) * | 2022-09-14 | 2026-04-09 | Hainan Simcere Zaiming Pharmeceutical Co., Ltd. | Polycyclic compound and use thereof |
| TW202508568A (zh) | 2023-04-07 | 2025-03-01 | 瑞典商阿斯特捷利康公司 | Ｉｒａｋ４蛋白水解靶向嵌合體 |
| PE20260301A1 (es) | 2023-06-14 | 2026-02-10 | Astrazeneca Ab | Derivados de 3-[3-amino-6-(2-hidroxifenil)piridazin-4-il]-3,8-diazabiciclo[3.2.1]octano como protacs degradantes de smarca2 para el tratamiento del cancer |
| PE20260307A1 (es) * | 2023-06-14 | 2026-02-11 | Astrazeneca Ab | Degradadores de smarca2 y usos de estos |
| CN121773112A (zh) * | 2023-08-17 | 2026-03-31 | 海思科医药集团股份有限公司 | 一种氰基芳香环衍生物及其在医药上的应用 |
| TW202530192A (zh) | 2023-09-22 | 2025-08-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 新穎化合物 |
| CN117430605A (zh) * | 2023-10-26 | 2024-01-23 | 广西天铭药业有限公司 | 一种kras g12c抑制剂amg-510中间体的合成方法 |
| WO2025114875A1 (en) * | 2023-12-01 | 2025-06-05 | Astrazeneca Ab | Er degraders and uses thereof |
| WO2025125575A1 (en) | 2023-12-14 | 2025-06-19 | Astrazeneca Ab | Irak4 protacs |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0422263D0 (en) | 2004-10-07 | 2004-11-10 | Glaxo Group Ltd | Novel compounds |
| AU2011239966B2 (en) | 2010-04-16 | 2014-05-08 | Ac Immune S.A. | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| WO2014210255A1 (en) | 2013-06-26 | 2014-12-31 | Abbvie Inc. | Primary carboxamides as btk inhibitors |
| JP2017528498A (ja) | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター |
| WO2016105518A1 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| IL312367A (en) * | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| WO2019057757A1 (en) * | 2017-09-20 | 2019-03-28 | Astrazeneca Ab | 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| CN120698983A (zh) * | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
-
2021
- 2021-09-29 CA CA3195695A patent/CA3195695A1/en active Pending
- 2021-09-29 CR CR20230185A patent/CR20230185A/es unknown
- 2021-09-29 PE PE2023001220A patent/PE20230782A1/es unknown
- 2021-09-29 EP EP21787317.3A patent/EP4221756A1/en active Pending
- 2021-09-29 AU AU2021353968A patent/AU2021353968B2/en active Active
- 2021-09-29 CN CN202180065971.2A patent/CN116249554A/zh active Pending
- 2021-09-29 MX MX2023003564A patent/MX2023003564A/es unknown
- 2021-09-29 WO PCT/EP2021/076752 patent/WO2022069520A1/en not_active Ceased
- 2021-09-29 IL IL301626A patent/IL301626A/en unknown
- 2021-09-29 BR BR112023005708A patent/BR112023005708A2/pt unknown
- 2021-09-29 US US18/247,014 patent/US20230374007A1/en active Pending
- 2021-09-29 JP JP2023519522A patent/JP2023543299A/ja active Pending
- 2021-09-29 KR KR1020237014514A patent/KR20230079408A/ko active Pending
-
2023
- 2023-03-24 DO DO2023000062A patent/DOP2023000062A/es unknown
- 2023-03-27 CL CL2023000881A patent/CL2023000881A1/es unknown
- 2023-04-24 CO CONC2023/0005188A patent/CO2023005188A2/es unknown
- 2023-04-27 EC ECSENADI202330959A patent/ECSP23030959A/es unknown
-
2025
- 2025-01-09 AU AU2025200137A patent/AU2025200137A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021353968B2 (en) | 2024-10-10 |
| WO2022069520A1 (en) | 2022-04-07 |
| AU2025200137A1 (en) | 2025-01-30 |
| MX2023003564A (es) | 2023-04-04 |
| DOP2023000062A (es) | 2023-05-31 |
| KR20230079408A (ko) | 2023-06-07 |
| AU2021353968A1 (en) | 2023-06-08 |
| CR20230185A (es) | 2023-06-27 |
| AU2021353968A9 (en) | 2024-10-03 |
| ECSP23030959A (es) | 2023-05-31 |
| CO2023005188A2 (es) | 2023-05-19 |
| CA3195695A1 (en) | 2022-04-07 |
| CL2023000881A1 (es) | 2023-11-17 |
| US20230374007A1 (en) | 2023-11-23 |
| PE20230782A1 (es) | 2023-05-09 |
| IL301626A (en) | 2023-05-01 |
| JP2023543299A (ja) | 2023-10-13 |
| CN116249554A (zh) | 2023-06-09 |
| EP4221756A1 (en) | 2023-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023005708A2 (pt) | Compostos e seu uso no tratamento do câncer | |
| BR112021019007A2 (pt) | Protacs que degradam o receptor de estrogênio | |
| JOP20240124A1 (ar) | مركبات 2-أمينو-3-سيانو ثيوفين حلقية ومشتقاتها لعلاج السرطان | |
| BR112022007783A2 (pt) | Composto, composição farmacêutica, e, métodos para inibir proteína g12c de kras e para tratar câncer | |
| BR112022021514A2 (pt) | [1,3]diazino[5,4-d]pirimidinas como inibidores de her2 | |
| JOP20220325A1 (ar) | مركبات 2-أمينو-3-سيانو ثيوفين تتألف من حلقات ومشتقات لعلاج السرطان | |
| BRPI0512796A (pt) | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf, e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença | |
| JOP20210319A1 (ar) | مركبات بيروليدين | |
| BRPI0515446A (pt) | amidas bicìclicas como inibidores de cinases | |
| BR112019012217A2 (pt) | compostos de amino-triazolopiridina e seu uso no tratamento de câncer | |
| BRPI0606930A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, métodos para a produção de um efeito de inibição de b-raf em um animal de sangue quente, para a produção de um efeito anti-cáncer em um animal de sangue quente e para o tratamento de doenças de um animal em um animal de sangue quente | |
| BRPI0512075A (pt) | composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença | |
| BRPI0414330A (pt) | composto, processo para preparação do mesmo, métodos para produção de um efeito antibacteriano, para inibição de dna girase bacteriana, e para tratamento de uma infecção bacteriana em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
| BR112022025117A2 (pt) | 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1 | |
| SK138497A3 (en) | A pharmaceutical composition containing benzimidazole for inhibiting the growth of cancers | |
| MX2024014117A (es) | Sales de ácido piperidinil-metil-purina-amina-d-tartárico, formas cristalinas y su uso en el tratamiento de enfermedades y condiciones médicas | |
| BR112018070536A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| BRPI0514679A (pt) | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença ou condição | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| BR112023000142A2 (pt) | Derivados de benzodiazepina úteis no tratamento de infecção pelo vírus sincicial respiratório | |
| BRPI0719920B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário | |
| BR112023005005A2 (pt) | Inibidores não covalentes da cinase 7 dependente de ciclina (cdk7) | |
| JOP20220281A1 (ar) | مركبات وتركيبات لتثبيط نشاط hif2 ألفا وطرق لاستخدامها | |
| BR112022008039A2 (pt) | Compostos de 4-amino-imidazoquinolina e usos relacionados | |
| BR112022018173A2 (pt) | Composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, composto para o uso e uso de um composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo |